BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12756494)

  • 1. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
    Onur R; Ilhan N; Orhan I; Ilhan N
    World J Urol; 2003 May; 21(1):43-7. PubMed ID: 12756494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance and limitations of f/tPSA in differential diagnosis of prostate cancer with tPSA levels between 4 and 10 ng/ml].
    Chen ZD; Wei SM; Cai SL
    Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):593-5. PubMed ID: 15265401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
    Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
    Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
    Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
    Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
    Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer.
    Oberpenning F; Weining C; Brandt B; De Angelis G; Heinecke A; Hamm M; Stieber P; Hertle L; Schmid HP; Semjonow A
    Clin Chem Lab Med; 2003 Jan; 41(1):90-4. PubMed ID: 12636056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
    Sakai I; Harada K; Hara I; Eto H; Miyake H
    Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA.
    Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G
    Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current usefulness of free/total PSA ratio in the diagnosis of prostate cancer at an early stage.
    Pfister C; Basuyau JP;
    World J Urol; 2005 Sep; 23(4):236-42. PubMed ID: 16096832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum free prostate-specific antigen in the diagnosis of prostate cancer.
    Leung HY; Lai LC; Day J; Thomson J; Neal DE; Hamdy FC
    Br J Urol; 1997 Aug; 80(2):256-9. PubMed ID: 9284198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA.
    Patel D; White PA; Milford Ward A
    BJU Int; 2000 Apr; 85(6):686-9. PubMed ID: 10759666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
    Abrahamsson PA; Kuriyama M
    Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of free/total PSA ratio and PSA density in distinguishing benign prostatic hypertrophy from prostatic cancer].
    Mosquera Madera J; Pinto Sierra I; Enguix Armada A; Sahagún Argüello JL
    Actas Urol Esp; 2001 Oct; 25(9):651-5. PubMed ID: 11765549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.